juvenile dermatomyositis
Conditions
Interventions
None listed
Sponsors
Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [Juvenile dermatomyositis (JDM) patients] Participants must meet all of the following criteria: 1. Age >= 3 years at the time of consent 2. Newly diagnosed cases classified as definite or probable idiopathic inflammatory myopathy (IIM) according to the 2017 EULAR/ACR classification criteria, and meeting all of the following conditions: a) Age at disease onset < 18 years b) Presence of heliotrope rash, Gottron's papules, or Gottron's sign (not required in anti-NXP2 antibody positive cases) c) Score thresholds: >= 7.5 (definite) or >= 5.5 (probable) without muscle biopsy, and >= 8.7 (definite) or >= 6.7 (probable) with muscle biopsy In addition, the Japanese diagnostic guideline for the Specified Chronic Pediatric Diseases Program is also reviewed as a reference 3. No prior treatment with the following: a) Systemic glucocorticoids b) Immunosuppressive agents (e.g., methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine) c) Targeted therapies (e.g., rituximab, abatacept, belimumab, anifrolumab, tocilizumab, anti-TNF agents, JAK inhibitors) 4. Written informed consent obtained from a parent or legal guardian [Controls] Participants must meet all of the following criteria: 1. Age >= 3 years at the time of consent 2. No history of immune mediated or chronic inflammatory diseases and not receiving long term immunosuppressive therapy (e.g., patients with food allergy) 3. Written informed consent obtained from a parent or legal guardian
Exclusion criteria
Exclusion criteria: Individuals deemed inappropriate for participation in this study by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cell type-specific gene expression profiles and expression quantitative trait loci (eQTL) effects in peripheral blood mononuclear cells in patients with juvenile dermatomyositis (JDM) before treatment initiation and at 1 year after treatment initiation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Identification of immunological and immunogenetic characteristics associated with differences in myositis-specific autoantibodies (MSAs) 2. Identification of immunological and immunogenetic characteristics associated with differences in clinical features (e.g., disease activity and organ involvement) 3. Identification of JDM-specific immunological and immunogenetic characteristics through comparison with adult-onset dermatomyositis | — |
Countries
Japan
Contacts
Public ContactYuzaburo Inoue
Chiba University Graduate School of Medicine, Department of General Medical Science
Outcome results
None listed